Hyderabad-based drugmaker, Natco Pharma reported a consolidated net profit of 275.8 crore in the fourth quarter of FY23, as against a net loss of 50.5 crore a year ago same period. Sequentially, the company posted a whopping 344.8% growth in Q4FY23 PAT. In December 2022 quarter, NATCO posted a net profit of 62.3 crore. Furthermore, the company’s revenue climbed by 51.80% to 926.9 crore as against 610.6 crore during Q4FY22. Compared to the preceding quarter, the growth was massive by 82.3%. Natco said, the increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in the ensuing years. Read here: For the full year FY23, Natco posted a consolidated total revenue of 2811.7 crore as against 2043.8 crore for the last year, reflecting 37.6% growth. The net profit for the period, on a consolidated basis, was 715.3 crore, as against 170 crore last year. Natco plans to incorporate a subsidiary company in Colombia with an investment up to an amount not exceeding $ 1,00,000. Also, the company is set to acquire a 100% stake in the UK-based company, Zista Pharma. Read here: Post the acquisition, Zista will become a wholly-owned subsidiary of Natco Pharma. After the Q4 results, Natco’s share price closed at 635.10 apiece up by 0.91% on BSE. The stock has touched an intraday high of 659.35 crore due to healthy quarterly earnings.